Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Operating Leases (2023 - 2026)

Contineum Therapeutics' Operating Leases history spans 4 years, with the latest figure at $7.0 million for Q1 2026.

  • Quarterly Operating Leases rose 52.94% to $7.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Mar 2026, up 52.94% year-over-year, with the annual reading at $8.2 million for FY2025, 71.62% up from the prior year.
  • Operating Leases came in at $7.0 million for Q1 2026, down from $8.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.2 million in Q4 2025 to a low of $108000.0 in Q4 2023.
  • The 4-year median for Operating Leases is $4.3 million (2025), against an average of $3.7 million.
  • Year-over-year, Operating Leases soared 4350.93% in 2024 and then surged 52.94% in 2026.
  • Contineum Therapeutics' Operating Leases stood at $108000.0 in 2023, then skyrocketed by 4350.93% to $4.8 million in 2024, then surged by 71.62% to $8.2 million in 2025, then decreased by 15.71% to $7.0 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Operating Leases are $7.0 million (Q1 2026), $8.2 million (Q4 2025), and $4.0 million (Q3 2025).